Cargando…
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
BACKGROUND: Gemcitabine (2′, 2′ –difluorodeoxycytidine) is one of many nonplatinum drugs that exhibit activity in recurrent, platinum-resistant ovarian cancer. However, the molecular mechanisms by which Gemcitabine treatment inhibits the proliferation of platinum-resistant ovarian cancer cells still...
Autores principales: | Kawaguchi, Hiroshi, Terai, Yoshito, Tanabe, Akiko, Sasaki, Hiroshi, Takai, Masaaki, Fujiwara, Satoe, Ashihara, Keisuke, Tanaka, Yoshimichi, Tanaka, Tomohito, Tsunetoh, Satoshi, Kanemura, Masanori, Ohmichi, Masahide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234938/ https://www.ncbi.nlm.nih.gov/pubmed/24713296 http://dx.doi.org/10.1186/1757-2215-7-38 |
Ejemplares similares
-
The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer
por: Takai, Masaaki, et al.
Publicado: (2014) -
GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer
por: Fujiwara, Satoe, et al.
Publicado: (2012) -
Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer
por: Tanaka, Yoshimichi, et al.
Publicado: (2013) -
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017) -
CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer
por: TANAKA, TOMOHITO, et al.
Publicado: (2015)